The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.
Siemens Healthineers will use the technology, which Quanterix acquired as part of its buy of UmanDiagnostics, to develop blood-based Nf-L clinical tests.
In a study published this week, researchers presented a Simoa-based assay for tuberculosis that could ultimately be packaged as a point-of-care test.
A recent study from UCSF suggests Abbott's blood-based i-Stat Alinity device may be able to identify TBI that isn't found by a CT scan.
A UPenn research team has developed a proof-of-principle detection platform that uses microbubbles to make target protein molecules visible and detectable.
The firm said that its lateral flow test may enable sports teams and paramedics to quickly decide whether there's a concussion or not.
The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.
The firm expects to use proceeds from the offering to expand its life sciences commercial operations, and improve and update its Simoa technology and instruments, among other initiatives.
The company expects the rollout of more reliable, user-friendly platforms will increase instrument usage among a substantial segment of its customer base.